![Jay Cross](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jay Cross
Finanzdirektor/CFO bei
Senti Biosciences, Inc.
Vermögen: - $ am 30.06.2026
Profil
John Harry Cross is currently Chief Financial Officer at Senti Biosciences Holdings, Inc. since 2026 and Chief Financial Officer at Senti Biosciences, Inc. since 2025.
Formerly, Mr. Cross was Chief Financial Officer, Treasurer & Secretary at Sonnet BioTherapeutics Holdings, Inc. from 2019 to 2025, Managing Director-Healthcare Investment Banking at Chardan Capital Markets LLC from 2015 to 2019, Director at Alere Financial Partners from 2014 to 2015, and Chief Financial & Business Officer at Sonnet BioTherapeutics, Inc. Education includes undergraduate studies at Washington & Lee University and graduate studies at Yale School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
-.--% | 27.03.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Jay Cross
| Unternehmen | Position | Beginn |
|---|---|---|
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Finanzdirektor/CFO | 03.03.2025 |
Ehemalige bekannte Positionen von Jay Cross
| Unternehmen | Position | Ende |
|---|---|---|
| SONNET BIOTHERAPEUTICS | Finanzdirektor/CFO | 21.02.2025 |
Chardan Capital Markets LLC
 Chardan Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01.03.2019 |
Alere Financial Partners
 Alere Financial Partners Investment ManagersFinance Provides investment research | Direktor/Vorstandsmitglied | 01.06.2015 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Finanzdirektor/CFO | - |
Ausbildung von Jay Cross
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
7
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Washington & Lee University
 Washington & Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chardan Capital Markets LLC
Chardan Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Alere Financial Partners
Alere Financial Partners Investment ManagersFinance Provides investment research | Finance |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Sonnet BioTherapeutics Holdings, Inc.
 Sonnet BioTherapeutics Holdings, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
